Drug Information

Drug (ID: DG01824) and It's Reported Resistant Information

• Name: Mangostin
• Synonyms: Alpha-Mangostin; Mangostin; 6147-11-1; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-en-1-yl)-9H-xanthen-9-one; Mangostine; Alpha-Mangostin, 95%; a-Mangostin; NSC27593; NSC30552; NSC-30552; UNII-U6RIV93RU1; U6RIV93RU1; CHEMBL323197; CHEBI:67547; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)xanthen-9-one; 1,3,6-trihydroxy-7-methoxy-2,8-diprenylxanthone; TNP00140; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-9H-xanthen-9-one; MFCD00135200; 3,6,8-trihydroxy-2-methoxy-1,7-bis(3-methylbut-2-enyl)xanthen-9-one; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)-9H-xanthen-9-one; 9H-Xanthen-9-one,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; Xanthen-9-one,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; 9H-Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; NSC 27593; NSC 30552; NSC 139154; Spectrum_001726; SpecPlus_000574; Spectrum2_001620; Spectrum3_001297; Spectrum4_001911; Spectrum5_000622; BSPBio_002933; KBioGR_002529; KBioSS_002206; BIDD:ER0576; DivK1c_006670; SCHEMBL354735; SPECTRUM1504015; SPECTRUM1505128; SPBio_001659; HSDB 8103; KBio1_001614; KBio2_002206; KBio2_004774; KBio2_007342; KBio3_002153; DTXSID00210420; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3,3-dimethylallyl)xanthone; ACT09245; BCP13253; HY-N0328; ZINC5430812; alpha-Mangostin, >=98% (HPLC); 1,7-bis(3-methylbut-2-enyl)-3,6,8-trihydroxy-2-methoxyxanthen-9-one; BDBM50214969; CCG-36465; NSC-27593; NSC139154; s3804; 9H-Xanthen-9-one,1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)-; AKOS015912806; AC-6089; CS-6435; DS-3359; MCULE-1080742368; NSC-139154; SDCCGMLS-0066796.P001; 1,3,6-Trihydroxy-7-methoxy-2,8-bis(3-methyl-2-buten-1-yl)-9H-xanthen-9-one; NCGC00017251-01; NCGC00017251-02; NCGC00017251-03; NCGC00017251-04; NCGC00017251-05; NCGC00095730-01; NCGC00095730-02; NCGC00095730-03; NCGC00178385-01; DB-053898; FT-0635997; M2793; N1590; N2590; W2645; 147M111; A833244; Q909638; SR-05000002649; Q-100010; SR-05000002649-1; BRD-K11991978-001-02-6; BRD-K11991978-001-03-4; 1,3,6-Trihydroxy-7-methoxy-2,8-di(3-methyl-2-butenyl)xanthone; 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methylbut-2-enyl)-9-xanthenone; 1,3,6-Trihydroxy-7-methoxy-2,8-bis-(3-methyl-but-2-enyl)-xanthen-9-one; 2-methoxy-1,7-bis(3-methylbut-2-enyl)-3,6,8-tris(oxidanyl)xanthen-9-one; (c) paragraph sign-mangostin pound>>alpha-Mangostin; NSC 139154; NSC 27593; NSC 30552; 9H-Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-buten-1-yl)-; 9H-Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)- (9CI); Xanthen-9-one, 1,3,6-trihydroxy-7-methoxy-2,8-bis(3-methyl-2-butenyl)- (8CI)
• Indication:
  In total 1 Indication(s)
  Discovery agent [ICD-11: N.A.]; Investigative; [1]
• Drug Resistance Disease(s):
  Disease(s) with Resistance Information Discovered by Cell Line Test for This Drug (1 diseases)
  Hyperglycemia [ICD-11: MA18]; [1]
• Target: Arachidonate 12-lipoxygenase (12-LOX); LOX12_HUMAN; [1]
• Target: Arachidonate 15-lipoxygenase (15-LOX); LOX15_HUMAN; [1]
• Target: Influenza Neuraminidase (Influ NA); NRAM_I33A0; [1]
• Formula: 5
• IsoSMILES: CC(=CCC1=C(C2=C(C=C1O)OC3=C(C2=O)C(=C(C(=C3)O)OC)CC=C(C)C)O)C
• InChI: InChI=1S/C24H26O6/c1-12(2)6-8-14-16(25)10-19-21(22(14)27)23(28)20-15(9-7-13(3)4)24(29-5)17(26)11-18(20)30-19/h6-7,10-11,25-27H,8-9H2,1-5H3
• InChIKey: GNRIZKKCNOBBMO-UHFFFAOYSA-N
• PubChem CID: 5281650
• ChEBI ID: CHEBI:67547
• TTD Drug ID: D06PRC

Type(s) of Resistant Mechanism of This Drug

  EADR: Epigenetic Alteration of DNA, RNA or Protein

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-21: Symptoms/clinical signs/unclassified clinical findings

Hyperglycemia [ICD-11: MA18]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Epigenetic Alteration of DNA, RNA or Protein (EADR)

Key Molecule: H19, imprinted maternally expressed transcript (H19) [1]

• Molecule Alteration: Down-regulation; Interaction
• Resistant Disease: Hyperglycemia [ICD-11: MA18.0]
• Experimental Note: Revealed Based on the Cell Line Data
• In Vitro Model: HUVEC-12 cells; Endothelium; Homo sapiens (Human); N.A.
• Experiment for Molecule Alteration: RNA-seq assay
• Experiment for Drug Resistance: CCK8 assay
• Mechanism Description: H19 exerted its function via the modulation of H19/miR-140/HE4 in hyperglycemia with alpha-Mangostin.

References

• Ref 1: Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axisAnticancer Drugs. 2020 Jun;31(5):473-482. doi: 10.1097/CAD.0000000000000888.